Cargando…

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is a novel multiple receptor tyrosine kinase inhibitor used for hepatocellular carcinoma (HCC) treatment. Although its main function is to suppress VEGFR and FGFR pathway, its immunomodulatory activity in HCC is not elucidated. Thus, this study aimed to investigate the immunom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jie, Fang, Peiqi, Wang, Chong, Gu, Meixiu, Pan, Baishen, Guo, Wei, Yang, Xinrong, Wang, Beili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607247/ https://www.ncbi.nlm.nih.gov/pubmed/34605616 http://dx.doi.org/10.1002/cam4.4312

Ejemplares similares

Clinical application of a fully automated blood collection robot and its assessment of blood collection quality of anticoagulant specimens
por: Wang, Chong, et al.
Publicado: (2023)

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Mean Corpuscular Volume Predicts In-Stent Restenosis Risk for Stable Coronary Artery Disease Patients Receiving Elective Percutaneous Coronary Intervention
por: Sun, Lin, et al.
Publicado: (2019)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
por: Finn, Richard S., et al.
Publicado: (2021)

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
por: Matsuki, Masahiro, et al.
Publicado: (2018)

Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
por: Deng, Haijing, et al.
Publicado: (2021)

A novel inflammation‐based nomogram system to predict survival of patients with hepatocellular carcinoma
por: Chen, Jinbin, et al.
Publicado: (2018)

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
por: Kimura, Takayuki, et al.
Publicado: (2018)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
por: Tao, Meng, et al.
Publicado: (2023)

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
por: Motzer, Robert, et al.
Publicado: (2023)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma
por: Nagai, Hidenari, et al.
Publicado: (2023)

Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score‐matched survival analysis
por: Gao, Yang, et al.
Publicado: (2019)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study
por: Mao, Kai, et al.
Publicado: (2018)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
por: Goyal, Manjeet Kumar, et al.
Publicado: (2023)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma
por: Gu, Xuefeng, et al.
Publicado: (2020)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Genetic variants of cell cycle pathway genes predict disease‐free survival of hepatocellular carcinoma
por: Liu, Shun, et al.
Publicado: (2017)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients
por: Yang, Anli, et al.
Publicado: (2018)

Impact of preoperative TACE on incidences of microvascular invasion and long‐term post‐hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis
por: Yang, Yun, et al.
Publicado: (2021)

A practical nomogram and risk stratification system predicting the cancer‐specific survival for patients with early hepatocellular carcinoma
por: Yan, Bing, et al.
Publicado: (2020)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma
por: Legros, Laurence, et al.
Publicado: (2023)

Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma
por: Zhou, Xiaohan, et al.
Publicado: (2021)

The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease
por: An, Jihyun, et al.
Publicado: (2019)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Does marital status impact postoperative survival in patients with less differentiated hepatocellular carcinoma? A population‐based study
por: Yan, Bing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m82a7fq1e4e2m52emvrdd5b2or